Nanobiotix Finalizes $100M Global Offering with Full Over-Allotment Exercise

summarizeSummary

Nanobiotix has completed its global offering, raising $100 million after underwriters fully exercised their over-allotment option, securing funding into 2029.

check_boxKey Events

• Offering Finalized

  Underwriters fully exercised their over-allotment option for the global offering, increasing the total capital raised.

• Capital Raised

  The global offering, including the over-allotment, generated approximately $100 million in gross proceeds for the company.

• Cash Runway Extended

  The company expects these proceeds, combined with existing cash, to fund operations into 2029.

• Pricing Details

  The offering was priced at $38.98 per ADS, which represents a 14.92% discount to the volume-weighted average price of ordinary shares on Euronext Paris.

auto_awesomeAnalysis

This filing confirms the full exercise of the underwriters' over-allotment option, increasing the total gross proceeds from the global offering to $100 million. This capital raise, though dilutive and priced at a discount, significantly extends Nanobiotix's cash runway into 2029, providing crucial financial stability for its clinical development programs. The full exercise of the option indicates strong investor demand for the offering.